584 related articles for article (PubMed ID: 25935787)
1. The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema.
Brown GC; Brown MM; Turpcu A; Rajput Y
Ophthalmology; 2015 Jul; 122(7):1416-25. PubMed ID: 25935787
[TBL] [Abstract][Full Text] [Related]
2. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
Brown MM; Brown GC; Brown HC; Peet J
Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
[TBL] [Abstract][Full Text] [Related]
3. Cost-Utility Analysis of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
Brown GC; Brown MM; Monigle MC
Ophthalmol Retina; 2024 May; 8(5):431-446. PubMed ID: 37981235
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness and cost-effectiveness of the implantable miniature telescope.
Brown GC; Brown MM; Lieske HB; Lieske PA; Brown KS; Lane SS
Ophthalmology; 2011 Sep; 118(9):1834-43. PubMed ID: 21723614
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema.
Stein JD; Newman-Casey PA; Kim DD; Nwanyanwu KH; Johnson MW; Hutton DW
Ophthalmology; 2013 Sep; 120(9):1835-42. PubMed ID: 23642372
[TBL] [Abstract][Full Text] [Related]
6. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
Brown GC; Brown MM; Rapuano S; Boyer D
Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050
[TBL] [Abstract][Full Text] [Related]
7. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE.
Bressler NM; Varma R; Suñer IJ; Dolan CM; Ward J; Ehrlich JS; Colman S; Turpcu A;
Ophthalmology; 2014 Dec; 121(12):2461-72. PubMed ID: 25148789
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.
Dewan V; Lambert D; Edler J; Kymes S; Apte RS
Ophthalmology; 2012 Aug; 119(8):1679-84. PubMed ID: 22503301
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial.
Ross EL; Hutton DW; Stein JD; Bressler NM; Jampol LM; Glassman AR;
JAMA Ophthalmol; 2016 Aug; 134(8):888-96. PubMed ID: 27280850
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
[TBL] [Abstract][Full Text] [Related]
11. Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials.
Domalpally A; Ip MS; Ehrlich JS
Ophthalmology; 2015 Apr; 122(4):779-86. PubMed ID: 25601535
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.
Ip MS; Domalpally A; Sun JK; Ehrlich JS
Ophthalmology; 2015 Feb; 122(2):367-74. PubMed ID: 25439595
[TBL] [Abstract][Full Text] [Related]
13. Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
Hutton DW; Stein JD; Glassman AR; Bressler NM; Jampol LM; Sun JK;
JAMA Ophthalmol; 2019 Dec; 137(12):1424-1432. PubMed ID: 31647496
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of ranibizumab in the treatment of visual impairment due to diabetic macular edema.
Haig J; Barbeau M; Ferreira A
J Med Econ; 2016 Jul; 19(7):663-71. PubMed ID: 26882365
[TBL] [Abstract][Full Text] [Related]
15. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.
Nguyen QD; Brown DM; Marcus DM; Boyer DS; Patel S; Feiner L; Gibson A; Sy J; Rundle AC; Hopkins JJ; Rubio RG; Ehrlich JS;
Ophthalmology; 2012 Apr; 119(4):789-801. PubMed ID: 22330964
[TBL] [Abstract][Full Text] [Related]
16. Clinical applications of cost analysis of diabetic macular edema treatments.
Smiddy WE
Ophthalmology; 2012 Dec; 119(12):2558-62. PubMed ID: 23062655
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial.
Mitchell P; Annemans L; Gallagher M; Hasan R; Thomas S; Gairy K; Knudsen M; Onwordi H
Br J Ophthalmol; 2012 May; 96(5):688-93. PubMed ID: 22399690
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.
Brown DM; Nguyen QD; Marcus DM; Boyer DS; Patel S; Feiner L; Schlottmann PG; Rundle AC; Zhang J; Rubio RG; Adamis AP; Ehrlich JS; Hopkins JJ;
Ophthalmology; 2013 Oct; 120(10):2013-22. PubMed ID: 23706949
[TBL] [Abstract][Full Text] [Related]
19. Cataract surgery cost utility revisited in 2012: a new economic paradigm.
Brown GC; Brown MM; Menezes A; Busbee BG; Lieske HB; Lieske PA
Ophthalmology; 2013 Dec; 120(12):2367-2376. PubMed ID: 24246824
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.
Stein JD; Newman-Casey PA; Mrinalini T; Lee PP; Hutton DW
Ophthalmology; 2014 Apr; 121(4):936-45. PubMed ID: 24405740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]